Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.120
-0.180 (-4.19%)
At close: Mar 9, 2026, 4:00 PM EDT
4.120
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Bolt Biotherapeutics Revenue
Bolt Biotherapeutics had revenue of $2.17M in the quarter ending September 30, 2025, with 90.10% growth. This brings the company's revenue in the last twelve months to $5.20M, down -46.88% year-over-year. In the year 2024, Bolt Biotherapeutics had annual revenue of $7.69M, down -2.36%.
Revenue (ttm)
$5.20M
Revenue Growth
-46.88%
P/S Ratio
1.59
Revenue / Employee
$129,875
Employees
40
Market Cap
7.91M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CollPlant Biotechnologies | 2.48M |
| SeaStar Medical Holding | 881.00K |
| Iterum Therapeutics | 390.00K |
| Addex Therapeutics | 198.82K |
| Alaunos Therapeutics | 6.00K |
| Ernexa Therapeutics | 1,000.00 |
BOLT News
- 13 days ago - Bolt Biotherapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 11 months ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
- 11 months ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire